Transforming growth factor beta–activated kinase 1 (TAK1)

Transforming growth factor beta–activated kinase 1 (TAK1) is a serine/threonine kinase belonging to the MAP kinase kinase kinase (MAP3K) family, also known as MAP3K7[1][2][4]. TAK1 integrates signals from cytokines such as TGF-β, TNF-α, and interleukin-1, as well as from Toll-like receptors, transmitting these inputs to critical proinflammatory and stress response pathways including NF-κB and MAPK pathways (p38, JNK)[1][4][6]. TAK1 is essential for cell survival, particularly in immune cells such as dendritic cells, where it acts as an anti-apoptotic and pro-developmental checkpoint[5]. TAK1 activity is tightly controlled by phosphorylation and interaction with adaptor proteins (e.g., TAB1, TAB2, TAB3), enabling it to regulate a wide array of biological processes, including immune regulation, inflammation, response to infection, and tissue development[3][4][5]. Given its central role in inflammation, immunity, cell survival, and disease pathogenesis—including cancer and chronic inflammatory disorders—TAK1 is a validated therapeutic target but also presents substantial challenges regarding selectivity and safety in drug development[4][5].

Other names

MAP kinase kinase kinase 7 (MAP3K7)TGF-β-activated kinase 1TAK1 serine/threonine-protein kinase

Inhibition of kinase activity to block downstream NF-κB and MAPK signaling Suppression of proinflammatory cytokine signaling Promotion of apoptosis by interfering with TAK1-mediated survival signals